Home>>Signaling Pathways>> Others>> Ceramidases>>D-NMAPPD

D-NMAPPD (Synonyms: (1R,2R)-B13,CAY10466)

Catalog No.GC13884

ceramidase inhibitor that induces apoptosis

Products are for research use only. Not for human use. We do not sell to patients.

D-NMAPPD Chemical Structure

Cas No.: 35922-06-6

Size Price Stock Qty
1mg
$40.00
In stock
5mg
$149.00
In stock
10mg
$278.00
In stock
50mg
$1,091.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

D-NMAPPD is potent inhibitor of the acid ceramidase inhibitor.

Acid ceramidase is the lipid hydrolase responsible for the degradation of ceramide into sphingosine and free fatty acids within lysosomes. Aberrant AC activity has been observed in several human cancers and Alzheimer's disease. Overexpression of AC may prevent insulin resistant (Type II) diabetes induced by free fatty acids [2].

In vitro: D-NMAPPD was a potent inhibitor of acid ceramidase with an IC50 of ~10 μmol/l. D-NMAPPD (500 μmol/l) reduced the alkaline ceramidase activity. Treatment of melanoma cells with D-NMAPPD elevated endogenous ceramide levels in all melanoma cell populations. In HaCaT keratinocytes and A375 melanoma cells, D-NMAPPD triggered Bcl-2 overexpression abolished apoptosis. High concentrations of D-NMAPPD showed significant cytotoxic effects on HaCaT and melanoma cells. In melanoma cell lines A375, M186, Mel2A, M221, treatment of with 25 μM D-NMAPPD for 24 h resulted in a strong accumulation of ceramide. D-NMAPPD inhibited cell proliferation in a concentration-dependent manner in HaCaT keratinocytes with an IC50 of ~7 μM. D-NMAPPD exhibited no antiproliferative effect on ceramide-resistant melanoma cells.

References:
[1] Raisova M, Goltz G, Bektas M, et al.  Bcl‐2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes[J]. FEBS letters, 2002, 516(1-3): 47-52.
[2] Park J H, Schuchman E H.  Acid ceramidase and human disease[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2006, 1758(12): 2133-2138.

Reviews

Review for D-NMAPPD

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for D-NMAPPD

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.